The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

NEW YORK--(BUSINESS WIRE)--The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at Teva Pharmaceutical Industries Ltd., according to Fitch Ratings.

TEL AVIV, July 14 (Reuters) - There will not be any generic version of Teva Pharmaceutical Industries' multiple sclerosis drug Copaxone before 2014, the company's president and chief executive said in ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

We are lowering our fair value estimate for Teva Pharmaceutical to $10 per share from $11, primarily as a result of our lower top-line forecast over the next two years. The company's first-quarter ...

NEW YORK (Reuters) - Momenta Pharmaceuticals Inc said on Friday U.S. regulators had accepted for review its generic version of Teva Pharmaceutical Industries Ltd's multiple sclerosis drug Copaxone, ...

Blue Cross and Blue Shield of Vermont and the Vermont Health Plan filed suit this week against Teva Pharmaceuticals, accusing the company of using some shady tactics to rake in money from its multiple ...